252 related articles for article (PubMed ID: 18789179)
1. Involvement of the endocannabinoid system in phencyclidine-induced cognitive deficits modelling schizophrenia.
Vigano D; Guidali C; Petrosino S; Realini N; Rubino T; Di Marzo V; Parolaro D
Int J Neuropsychopharmacol; 2009 Jun; 12(5):599-614. PubMed ID: 18789179
[TBL] [Abstract][Full Text] [Related]
2. Cannabinoid CB1 receptor antagonism prevents neurochemical and behavioural deficits induced by chronic phencyclidine.
Guidali C; Viganò D; Petrosino S; Zamberletti E; Realini N; Binelli G; Rubino T; Di Marzo V; Parolaro D
Int J Neuropsychopharmacol; 2011 Feb; 14(1):17-28. PubMed ID: 20196921
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of fatty-acid amide hydrolase and CB1 receptor antagonism differentially affect behavioural responses in normal and PCP-treated rats.
Seillier A; Advani T; Cassano T; Hensler JG; Giuffrida A
Int J Neuropsychopharmacol; 2010 Apr; 13(3):373-86. PubMed ID: 19607756
[TBL] [Abstract][Full Text] [Related]
4. Disruption of social cognition in the sub-chronic PCP rat model of schizophrenia: Possible involvement of the endocannabinoid system.
Seillier A; Giuffrida A
Eur Neuropsychopharmacol; 2016 Feb; 26(2):298-309. PubMed ID: 26706691
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of Δ9-tetrahydrocannabinol dosing on correlates of schizophrenia in the sub-chronic PCP rat model.
Seillier A; Martinez AA; Giuffrida A
PLoS One; 2020; 15(3):e0230238. PubMed ID: 32163506
[TBL] [Abstract][Full Text] [Related]
6. THC and endocannabinoids differentially regulate neuronal activity in the prefrontal cortex and hippocampus in the subchronic PCP model of schizophrenia.
Aguilar DD; Giuffrida A; Lodge DJ
J Psychopharmacol; 2016 Feb; 30(2):169-81. PubMed ID: 26510449
[TBL] [Abstract][Full Text] [Related]
7. Bacopa monnieri (Brahmi) improved novel object recognition task and increased cerebral vesicular glutamate transporter type 3 in sub-chronic phencyclidine rat model of schizophrenia.
Piyabhan P; Wannasiri S; Naowaboot J
Clin Exp Pharmacol Physiol; 2016 Dec; 43(12):1234-1242. PubMed ID: 27562725
[TBL] [Abstract][Full Text] [Related]
8. Bacopa monnieri (Brahmi) Enhanced Cognitive Function and Prevented Cognitive Impairment by Increasing VGLUT2 Immunodensity in Prefrontal Cortex of Sub-Chronic Phencyclidine Rat Model of Schizophrenia.
Piyabhan P; Wetchateng T
J Med Assoc Thai; 2015 Apr; 98 Suppl 3():S7-15. PubMed ID: 26387382
[TBL] [Abstract][Full Text] [Related]
9. Induction of metabolic hypofunction and neurochemical deficits after chronic intermittent exposure to phencyclidine: differential modulation by antipsychotic drugs.
Cochran SM; Kennedy M; McKerchar CE; Steward LJ; Pratt JA; Morris BJ
Neuropsychopharmacology; 2003 Feb; 28(2):265-75. PubMed ID: 12589379
[TBL] [Abstract][Full Text] [Related]
10. Cognitive enhancement effects of Bacopa monnieri (Brahmi) on novel object recognition and VGLUT1 density in the prefrontal cortex, striatum, and hippocampus of sub-chronic phencyclidine rat model of schizophrenia.
Piyabhan P; Wetchateng T
J Med Assoc Thai; 2013 May; 96(5):625-32. PubMed ID: 23745319
[TBL] [Abstract][Full Text] [Related]
11. Chronic infusion of PCP via osmotic mini-pumps: a new rodent model of cognitive deficit in schizophrenia characterized by impaired attentional set-shifting (ID/ED) performance.
Pedersen CS; Goetghebeur P; Dias R
J Neurosci Methods; 2009 Dec; 185(1):66-9. PubMed ID: 19761795
[TBL] [Abstract][Full Text] [Related]
12. Cognitive enhancement effects of Bacopa monnieri (Brahmi) on novel object recognition and NMDA receptor immunodensity in the prefrontal cortex and hippocampus of sub-chronic phencyclidine rat model of schizophrenia.
Piyabhan P; Wetchateng T; Sireeratawong S
J Med Assoc Thai; 2013 Feb; 96(2):231-8. PubMed ID: 23936991
[TBL] [Abstract][Full Text] [Related]
13. Animal model of schizophrenia: dysfunction of NMDA receptor-signaling in mice following withdrawal from repeated administration of phencyclidine.
Nabeshima T; Mouri A; Murai R; Noda Y
Ann N Y Acad Sci; 2006 Nov; 1086():160-8. PubMed ID: 17185514
[TBL] [Abstract][Full Text] [Related]
14. Chronic cannabinoid exposure reduces phencyclidine-induced schizophrenia-like positive symptoms in adult rats.
Spano MS; Fattore L; Cadeddu F; Fratta W; Fadda P
Psychopharmacology (Berl); 2013 Feb; 225(3):531-42. PubMed ID: 22903392
[TBL] [Abstract][Full Text] [Related]
15. Role of the endocannabinoid and endovanilloid systems in an animal model of schizophrenia-related emotional processing/cognitive deficit.
Almeida V; Levin R; Peres FF; Suiama MA; Vendramini AM; Santos CM; Silva ND; Zuardi AW; Hallak JEC; Crippa JA; Abílio VC
Neuropharmacology; 2019 Sep; 155():44-53. PubMed ID: 31103618
[TBL] [Abstract][Full Text] [Related]
16. Estradiol attenuates the cognitive deficits in the novel object recognition task induced by sub-chronic phencyclidine in ovariectomized rats.
Roseman AS; McGregor C; Thornton JE
Behav Brain Res; 2012 Jul; 233(1):105-12. PubMed ID: 22561127
[TBL] [Abstract][Full Text] [Related]
17. Dose-response effect of acute phencyclidine on functional connectivity and dopamine levels, and their association with schizophrenia-like symptom classes in rat.
Paasonen J; Salo RA; Ihalainen J; Leikas JV; Savolainen K; Lehtonen M; Forsberg MM; Gröhn O
Neuropharmacology; 2017 Jun; 119():15-25. PubMed ID: 28342897
[TBL] [Abstract][Full Text] [Related]
18. Δ9-tetrahydrocannabinol (Δ9-THC) administration after neonatal exposure to phencyclidine potentiates schizophrenia-related behavioral phenotypes in mice.
Rodríguez G; Neugebauer NM; Yao KL; Meltzer HY; Csernansky JG; Dong H
Pharmacol Biochem Behav; 2017 Aug; 159():6-11. PubMed ID: 28648819
[TBL] [Abstract][Full Text] [Related]
19. D(1)-like receptor activation improves PCP-induced cognitive deficits in animal models: Implications for mechanisms of improved cognitive function in schizophrenia.
McLean SL; Idris NF; Woolley ML; Neill JC
Eur Neuropsychopharmacol; 2009 Jun; 19(6):440-50. PubMed ID: 19268547
[TBL] [Abstract][Full Text] [Related]
20. Postnatal Phencyclidine (PCP) as a Neurodevelopmental Animal Model of Schizophrenia Pathophysiology and Symptomatology: A Review.
Grayson B; Barnes SA; Markou A; Piercy C; Podda G; Neill JC
Curr Top Behav Neurosci; 2016; 29():403-428. PubMed ID: 26510740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
